Traduction de «Forced excitation » (Anglais → Français) :

constrained current operation | forced excitation

constrained current operation forced excitation

constrained current operation | forced excitation

cyclic forces of hydrodynamic excitation

electronically excited oxygen atom [ electronically excited oxygen | excited oxygen atom | excited oxygen | excited atomic oxygen ]

electronically excited oxygen | electronically excited oxygen atom | excited oxygen | excited oxygen atom

Anomalous atrioventricular excitation Atrioventricular conduction:accelerated | accessory | pre-excitation | Lown-Ganong-Levine syndrome Wolff-Parkinson-White syndrome

excited state [ electronically excited state | excited level ]

cross-talk phenomenon artifact | cross talk phenomenon artifact | cross-talk artifact | cross excitation phenomenon artifact | cross-excitation phenomenon artifact | cross-excitation artifact

selective excitation technique | tailored excitation technique

European Commissioner for Research, Innovation and Science, Máire Geoghegan-Quinn, said: "We are very happy to join forces with CERN to support one of the most exciting scientific projects in the Middle East.

In my introductory remarks I'll offer a brief history and perspective of Canada's army reserve; a refresher on the mission and the scope for the land force reserve restructure project; a view of some of the exciting initiatives we've undertaken to transform the army reserve, in concert with the rest of the army; where my mandate fits into the overall army transformation; some of the funding and risk management challenges; and an exciting concept derived from our recent conference on reserves in homeland defence, homeland security ...[+++] that was sponsored by the centre for military and strategic studies at the University of Calgary.

Q-26 — Mr. Cummins (Delta—South Richmond) — With regard to the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence: (a) what deployments since 1990 involved administration of the drug to members of the Canadian Forces; (b) did Health Canada receive from the Canadian Forces adverse drug event reports for each such deployment either during or immediately following deployment; (c) how many Canadians received the drug under Health Canada’s Lariam Safety Monitoring Study; (d) how many patients were the subject of monitoring reports received by Health Canada directly or indirectly from ...[+++] Roche under the Lariam Safety Monitoring Study; (e) what types of adverse events were identified by the Lariam Safety Monitoring Study up to the time the drug was licensed in 1993; (f) what is the total number of adverse events reported to Health Canada since the commencement of marketing in 1993; (g) how many adverse events were reported to Health Canada since the commencement of the marketing of the drug in 1993 involving each of the following reactions - hallucinations, panic reaction, hyper alertness, extreme excitability, convulsions, aggressive reaction, marked restlessness, suicide, suicidal tendency, suicide attempt, thoughts of self harm, abnormal dreams, emotional disorder, irritability, nightmares, abnormal thinking, anxiety, depressed state, aggravated depression, light-headedness, anxiety attack, mood swings, abnormal crying, psychosis, delusion, speech disorder, concentration impaired, fear, euphoria, hysteria, paranoid psychosis, memory impairment, emotional disorder, murder; (h) what measures have been taken by Health Canada to ensure that it receives notice of such adverse drug events from doctors administering the drug; (i) what changes to the product monograph have been approved by Health Canada since licensing of the drug in 1993; (j) how many Canadian Forces members deployed on special missions abroad sinc ...

[Text] Question No. 26 Mr. John Cummins: With regard to the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence: (a) what deployments since 1990 involved administration of the drug to members of the Canadian Forces; (b) did Health Canada receive from the Canadian Forces adverse drug event reports for each such deployment either during or immediately following deployment; (c) how many Canadians received the drug under Health Canada’s Lariam Safety Monitoring Study; (d) how many patients were the subject of monitoring reports received by Health Canada directly or indirectly from Ro ...[+++]che under the Lariam Safety Monitoring Study; (e) what types of adverse events were identified by the Lariam Safety Monitoring Study up to the time the drug was licensed in 1993; (f) what is the total number of adverse events reported to Health Canada since the commencement of marketing in 1993; (g) how many adverse events were reported to Health Canada since the commencement of the marketing of the drug in 1993 involving each of the following reactions - hallucinations, panic reaction, hyper alertness, extreme excitability, convulsions, aggressive reaction, marked restlessness, suicide, suicidal tendency, suicide attempt, thoughts of self harm, abnormal dreams, emotional disorder, irritability, nightmares, abnormal thinking, anxiety, depressed state, aggravated depression, light-headedness, anxiety attack, mood swings, abnormal crying, psychosis, delusion, speech disorder, concentration impaired, fear, euphoria, hysteria, paranoid psychosis, memory impairment, emotional disorder, murder; (h) what measures have been taken by Health Canada to ensure that it receives notice of such adverse drug events from doctors administering the drug; (i) what changes to the product monograph have been approved by Health Canada since licensing of the drug in 1993; (j) how many Canadian Forces members deployed on special missions abroad since 1 ...